Clean-Version of Amended Claims

Claim 1 (Currently amended). An A_1AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with $-COOR_1$ and wherein R_1 is alkyl.

Claim 2 (Canceled).

Claim 3 (Currently amended). The compound, according to claim 1, wherein said ester function has a structure selected from the group consisting of:





and salts thereof;

wherein R_1 is alkyl.

Claim 4 (Currently amended): A pharmaceutical composition comprising an A_1AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with $-COOR_1$ and wherein R_1 is alkyl;
wherein said composition further comprises a pharmaceutical carrier.

Claim 5 (Canceled):

Claim 6 (Original): The pharmaceutical composition, according to claim 4, wherein said ester function has a structure selected from the group consisting of:





and salts thereof;

wherein R_1 is alkyl.

Claim 7 (Currently amended): A method for inhibiting the A_1Ado receptor in an individual in need of divresis or treatment for congestive heart failure wherein said method comprises administering to said individual a pharmaceutical composition comprising an A_1AdoR antagonist that is a 1,3 dipropylxanthine with an ester function at the 8-position, wherein the ester function is a cycloalkyl substituted with $-COOR_1$ and wherein R_1 is alkyl.

Claim 8 (Canceled):

Claim 9 (Original): The method, according to claim 7, wherein said ester function has a structure selected from the group consisting of:





and salts thereof;

wherein R_1 is alkyl.

Claim 10 (Original): The method, according to claim 7, wherein the individual is a human.

Claim 11 (Original): The method, according to claim 7, wherein said individual has congestive heart failure.